Novavax could raise $50 million through at-the-market stock offering

Agent MLV helps company raise proceeds for general corporate purposes

By Devika Patel

Knoxville, Tenn., Oct. 2 - Novavax, Inc. negotiated a $50 million "at-the-market" offering of its common stock on Oct. 1, according to a prospectus supplement and 8-K filed Tuesday with the Securities and Exchange Commission.

MLV & Co. LLC is the underwriter and will be paid a 2% commission.

Proceeds will be used for general corporate purposes.

Based in Rockville, Md., Novavax develops vaccines against infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.